Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Sacubitril/valsartan after bypass to treat moderate ischemic mitral regurgitation

Official title: Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Run by China National Center for Cardiovascular Diseases · NCT06917664 · Data updated 2026-11-12

This trial will test whether the drug sacubitril/valsartan can reduce moderate ischemic mitral regurgitation in people with coronary artery disease who have had isolated coronary artery bypass grafting (CABG).

More Coronary Artery Disease trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment220 (estimated)
SponsorChina National Center for Cardiovascular Diseases
Government
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJune 5, 2025
Main results expectedDecember 2026
Study endsJune 2027
Registry record updatedAugust 27, 2025
Trial IDNCT06917664 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people with coronary artery disease who underwent isolated CABG and had moderate ischemic mitral regurgitation confirmed on two preoperative echocardiograms and who meet blood pressure and lab safety limits.

Probably not a fit

Patients with symptomatic low blood pressure, estimated GFR under 30 mL/min/1.73 m2, serum potassium over 5 mmol/L, a history of angioedema with ACE inhibitors/ARBs, or those receiving concurrent mitral valve intervention are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled trial testing sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) given after isolated CABG in patients with moderate ischemic mitral regurgitation. Patients are enrolled if they had moderate IMR confirmed on two consecutive preoperative transthoracic echocardiograms and meet safety labs and blood pressure criteria. The main outcome is change in mitral regurgitation severity and related cardiac remodeling measured by echocardiography over follow-up. Key exclusions include symptomatic hypotension, severe renal dysfunction, high serum potassium, history of angioedema with RAAS blockers, or concurrent mitral valve interventions.

Why it matters

Potential benefit: If successful, the treatment could reduce mitral regurgitation severity and improve heart function and symptoms, possibly avoiding additional mitral procedures.

How similar studies have gone: ARNI therapy (sacubitril/valsartan) has shown clear benefits in heart failure and some promise for reverse remodeling and reducing functional mitral regurgitation, but its specific use to treat ischemic MR after CABG is relatively novel and less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Fully informed and voluntarily signed informed consent;
2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )

Exclusion Criteria:

1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.

Where it's running

  • China National Center for Cardiovascular Diseases
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.